News
![Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings: https://www.marketbeat.com/logos/articles/med_20230518072749_vertex-pharmaceuticals-hits-record-high-on-strong.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGtTYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fe1fa8a76cffa1e1d1a7a5af6f98fc7532bc5f23/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230518072749_vertex-pharmaceuticals-hits-record-high-on-strong.jpg?locale=us)
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), maker of Cystic fibrosis drugs, rallied to a record high on May 2 after a better-than-expected first-quarter earnings report.
Net income of $3.05 a
![Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings: https://www.marketbeat.com/logos/articles/med_20230518072749_vertex-pharmaceuticals-hits-record-high-on-strong.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMGtTYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--fe1fa8a76cffa1e1d1a7a5af6f98fc7532bc5f23/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230518072749_vertex-pharmaceuticals-hits-record-high-on-strong.jpg?locale=us)
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), maker of Cystic fibrosis drugs, rallied to a record high on May 2 after a better-than-expected first-quarter earnings report.
Net income of $3.05 a
![Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential: https://www.marketbeat.com/logos/articles/med_20230517121722_analysts-say-these-2-mid-cap-biotechs-have-2x-pote.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeG9TYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--efb5d185d67469d755d9527a295e82f9c42ac310/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230517121722_analysts-say-these-2-mid-cap-biotechs-have-2x-pote.jpg?locale=us)
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
On May 15th, mid-cap biotechnology company Sarepta Therapeutics was the big winner in an otherwise quiet day for the Russell 1000 Index. Sarepta jumped more than 30% after an FDA advisory panel
![Saturn Oil & Gas Inc. Reports Q1 2023 Results and Record Production: https://www.irw-press.at/prcom/images/messages/2023/70599/Saturn_170523_ENPRcom.004.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNmNRYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--dfe1718b0f96e0cef29f22e19f3c3d1ee5d51975/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Saturn_170523_ENPRcom.004.png?locale=us)
Saturn Oil & Gas Inc. Reports Q1 2023 Results and Record Production
CALGARY, ALBERTA – May 16, 2023 - Saturn Oil & Gas Inc. (TSXV: SOIL)(FSE: SMKA)(OTCQX: OILSF)(“Saturn” or the “Company”) is pleased to report its financial and operating results for the three
![Saturn Oil & Gas Inc. gibt Ergebnisse für 1. Quartal 2023 und Rekordproduktion bekannt: https://www.irw-press.at/prcom/images/messages/2023/70599/Saturn_170523_DEPRcom.004.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNlFRYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--2ae4a6273fb7531fbea1a2791dc69f249162baac/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/Saturn_170523_DEPRcom.004.png?locale=us)
Saturn Oil & Gas Inc. gibt Ergebnisse für 1. Quartal 2023 und Rekordproduktion bekannt
Calgary (Alberta), 16. Mai 2023 / IRW-Press / - Saturn Oil & Gas Inc. (TSX-V: SOIL) (FWB: SMKA) (OTCQX: OILSF) („Saturn“ oder das „Unternehmen“) freut sich, seine Finanz- und
![The Turnaround for Weight Watchers is Taking Shape: https://www.marketbeat.com/logos/articles/med_20230514180546_charty-ww.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGdPYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ff351f66c02189ec9ff23c0f8c44db4d7d59a6ef/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230514180546_charty-ww.jpg?locale=us)
The Turnaround for Weight Watchers is Taking Shape
Weight management meals and services provider WW International Inc. (NYSE: WW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares collapsed (26%) as Artal Group S.A
![The Turnaround for Weight Watchers is Taking Shape: https://www.marketbeat.com/logos/articles/med_20230514180546_charty-ww.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNGdPYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--ff351f66c02189ec9ff23c0f8c44db4d7d59a6ef/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230514180546_charty-ww.jpg?locale=us)
The Turnaround for Weight Watchers is Taking Shape
Weight management meals and services provider WW International Inc. (NYSE: WW) stock made a 52-week high of $10.02 after its Q1 2023 earnings release. Shares collapsed (26%) as Artal Group S.A
![Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy: https://www.marketbeat.com/logos/articles/med_20230516050346_sarepta-soars-31-as-fda-panel-backs-muscular-dystr.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMVFPYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--a31cb6b4ac8302cca8e5e70e3f6ee5c85d029040/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230516050346_sarepta-soars-31-as-fda-panel-backs-muscular-dystr.jpg?locale=us)
Sarepta Soars 31% As FDA Panel Backs Muscular Dystrophy Therapy
Sarepta Therapeutics Inc. (NASDAQ: SRPT) jumped nearly 31% on May 15, after a Food and Drug Administration committee gave a thumbs up to the company’s experimental gene therapy to treat Duchenne
![Is Novavax Finally Turning Things Around?: https://www.marketbeat.com/logos/articles/med_20230514175918_chartt-nvax.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBKzBNYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--1adde23b9a3750d2f04deb8ca4ca0a45bf6b3fef/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230514175918_chartt-nvax.jpg?locale=us)
Is Novavax Finally Turning Things Around?
Vaccine developer Novavax Inc. (NASDAQ: NVAX) stock shot up 28% following its Q1 2023 earnings report. The company specializes in vaccines for infectious diseases, including COVID-19, influenza
![German International School of Silicon Valley wird für innovatives KI-Projekt mit hochdotiertem Preis der Deutschen Industrie- und Handelskammer (IHK) ausgezeichnet: https://www.irw-press.at/prcom/images/messages/2023/70502/GermanInternationalSchool_110523_DEPRcom.003.jpeg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNFFKYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--69267da7dcc2ba0d9abbf0e2be03b974f8f1a05d/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/GermanInternationalSchool_110523_DEPRcom.003.jpeg?locale=us)
German International School of Silicon Valley wird für innovatives KI-Projekt mit hochdotiertem Preis der Deutschen Industrie- und Handelskammer (IHK) ausgezeichnet
MOUNTAIN VIEW und SAN FRANCISCO, KALIFORNIEN / ACCESSWIRE / 11. Mai 2023 / Die German International School of Silicon Valley (GISSV) wurde im Rahmen des von der Deutschen Industrie- und
![ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results: https://www.marketbeat.com/logos/articles/med_20230507142135_chartt-imgn.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNEFEYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5c1a764fe2e456cda77e41a5778e3a020ec701a2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230507142135_chartt-imgn.jpg?locale=us)
ImmunoGen Nearly Triples on Ovarian Cancer Drug Phase 3 Results
Commercial-state biotechnology company ImmunoGen Inc. (NASDAQ: IMGN) shares more than doubled on phase 3 clinical trial results. Its ovarian cancer drug Elahere shows statistical improvements for
![Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales: https://www.marketbeat.com/logos/articles/med_20230504211613_regeneron-beats-q1-views-but-stock-drops-on-weak-e.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2tCYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--26208beaff1e53954dadcf470598a9dc71a7ffae/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230504211613_regeneron-beats-q1-views-but-stock-drops-on-weak-e.jpg?locale=us)
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) gapped down more than 6% on May 4, despite reporting better-than-expected first-quarter earnings and revenue.
Net income tumbled by 12% to $10.09 a
![Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales: https://www.marketbeat.com/logos/articles/med_20230504211613_regeneron-beats-q1-views-but-stock-drops-on-weak-e.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2tCYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--26208beaff1e53954dadcf470598a9dc71a7ffae/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230504211613_regeneron-beats-q1-views-but-stock-drops-on-weak-e.jpg?locale=us)
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) gapped down more than 6% on May 4, despite reporting better-than-expected first-quarter earnings and revenue.
Net income tumbled by 12% to $10.09 a
![Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales: https://www.marketbeat.com/logos/articles/med_20230504211613_regeneron-beats-q1-views-but-stock-drops-on-weak-e.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM2tCYXc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--26208beaff1e53954dadcf470598a9dc71a7ffae/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230504211613_regeneron-beats-q1-views-but-stock-drops-on-weak-e.jpg?locale=us)
Regeneron Beats Q1 Views, But Stock Drops On Weak Eye Med Sales
Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) gapped down more than 6% on May 4, despite reporting better-than-expected first-quarter earnings and revenue.
Net income tumbled by 12% to $10.09 a
![Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding: https://www.marketbeat.com/logos/articles/med_20230502115431_chart-canf.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMi84YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--9fa461efe4512eccd853447afe3a816d6464059f/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230502115431_chart-canf.jpg?locale=us)
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers, inflammatory diseases and sexual dysfunction. It
![High-Yield Pfizer Falls Off The COVID Cliff, And Survives: https://www.marketbeat.com/logos/articles/med_20230502093017_chart-pfe-522023.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM1Q4YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c311c303e106fc0d8d8d3da758dae9bcd621a7f1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230502093017_chart-pfe-522023.png?locale=us)
High-Yield Pfizer Falls Off The COVID Cliff, And Survives
Pfizer (NYSE: PFE) was expected to post a significant decline in revenue and earnings because of the slowing COVID business, and it did. However, the takeaway from the report is that business is
![High-Yield Pfizer Falls Off The COVID Cliff, And Survives: https://www.marketbeat.com/logos/articles/med_20230502093017_chart-pfe-522023.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBM1Q4YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--c311c303e106fc0d8d8d3da758dae9bcd621a7f1/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230502093017_chart-pfe-522023.png?locale=us)
High-Yield Pfizer Falls Off The COVID Cliff, And Survives
Pfizer (NYSE: PFE) was expected to post a significant decline in revenue and earnings because of the slowing COVID business, and it did. However, the takeaway from the report is that business is
![Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal: https://www.marketbeat.com/logos/articles/med_20230425102047_chart-viri.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNi84YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e765016dc4874369137a4917d444f93993635bd3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230425102047_chart-viri.jpg?locale=us)
Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal
Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia and other abnormal immune
![Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal: https://www.marketbeat.com/logos/articles/med_20230425102047_chart-viri.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBNi84YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e765016dc4874369137a4917d444f93993635bd3/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230425102047_chart-viri.jpg?locale=us)
Virios Therapeutics Up 75% on Fibromyalgia Phase 3 Proposal
Virios Therapeutics Inc. (NASDAQ: VIRI) is a developmental-stage biotechnology company specializing in novel antiviral therapies for treating fibromyalgia and other abnormal immune
![Why Legend Biotech Stock Is Having Its Best Month Yet: https://www.marketbeat.com/logos/articles/med_20230424135734_why-legend-biotech-stock-is-having-its-best-month.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN2I4YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e0fb704b76cef35f42fad2a7857b3b605b658608/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230424135734_why-legend-biotech-stock-is-having-its-best-month.jpg?locale=us)
Why Legend Biotech Stock Is Having Its Best Month Yet
Legend Biotech Corporation (NASDAQ: LEGN) is among the many healthcare names vying for a breakthrough in cancer treatment. Last week, the New Jersey-based company had just that.
On April 19th, a
![Why Legend Biotech Stock Is Having Its Best Month Yet: https://www.marketbeat.com/logos/articles/med_20230424135734_why-legend-biotech-stock-is-having-its-best-month.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN2I4YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e0fb704b76cef35f42fad2a7857b3b605b658608/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230424135734_why-legend-biotech-stock-is-having-its-best-month.jpg?locale=us)
Why Legend Biotech Stock Is Having Its Best Month Yet
Legend Biotech Corporation (NASDAQ: LEGN) is among the many healthcare names vying for a breakthrough in cancer treatment. Last week, the New Jersey-based company had just that.
On April 19th, a
![Why Legend Biotech Stock Is Having Its Best Month Yet: https://www.marketbeat.com/logos/articles/med_20230424135734_why-legend-biotech-stock-is-having-its-best-month.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBN2I4YWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--e0fb704b76cef35f42fad2a7857b3b605b658608/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230424135734_why-legend-biotech-stock-is-having-its-best-month.jpg?locale=us)
Why Legend Biotech Stock Is Having Its Best Month Yet
Legend Biotech Corporation (NASDAQ: LEGN) is among the many healthcare names vying for a breakthrough in cancer treatment. Last week, the New Jersey-based company had just that.
On April 19th, a
![Tilray Brands Consolidates Hold: Profits Will Drive Shares Higher: https://www.marketbeat.com/logos/articles/med_20230411111847_chart-tlry-4112023.png](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBMjNzYWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--5b874806835c1804583941f90cdf2baf500fa84e/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230411111847_chart-tlry-4112023.png?locale=us)
Tilray Brands Consolidates Hold: Profits Will Drive Shares Higher
Tilray Brands (NASDAQ: TLRY) reported a mixed quarter and a deal to acquire HEXO that sent the market moving lower. While the news is less than spectacular, there are some takeaways for
![Weight Watchers Reshapes Itself with a Game-Changer Acquisition: https://www.marketbeat.com/logos/articles/med_20230411112556_chartt-ww.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeVBzYWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d9fc96dd5bcfbc7ab9a86816e6a4fd4a7aa020a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230411112556_chartt-ww.jpg?locale=us)
Weight Watchers Reshapes Itself with a Game-Changer Acquisition
Weight management food and services provider WW International Inc. (NYSE: WW) stock took a 25% spike as it closed its acquisition of telehealth weight loss platform provider Sequence Inc. WW
![Weight Watchers Reshapes Itself with a Game-Changer Acquisition: https://www.marketbeat.com/logos/articles/med_20230411112556_chartt-ww.jpg](https://www.sharewise.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBeVBzYWc9PSIsImV4cCI6bnVsbCwicHVyIjoiYmxvYl9pZCJ9fQ==--3d9fc96dd5bcfbc7ab9a86816e6a4fd4a7aa020a/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9MY21WemFYcGxTU0lKTXpVd2VBWTZCa1ZVIiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--aa36f503a05c343bf077379e5dc8bce118d9db18/med_20230411112556_chartt-ww.jpg?locale=us)
Weight Watchers Reshapes Itself with a Game-Changer Acquisition
Weight management food and services provider WW International Inc. (NYSE: WW) stock took a 25% spike as it closed its acquisition of telehealth weight loss platform provider Sequence Inc. WW